학술논문
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Document Type
Article
Author
Liu, X.; Feng, S.; Aley, P.K.; Minassian, A.M.; Lambe, T.; Snape, M.D.; Munro, A.P.S.; Babbage, G.; Cathie, K.; Owens, D.R.; Pacurar, M.; Saich, S.; Read, R.C.; Faust, S.N.; Janani, L.; Cornelius, V.; Mujadidi, Y.F.; Baxter, D.; Mughal, M.; Bula, M.; Dodd, K.; Chatterjee, K.; Dejnirattisai, W.; Screaton, G.R.; Supasa, P.; Enever, Y.; Qureshi, E.; Green, C.A.; Goodman, A.L.; Serafimova, T.; Harndahl, L.; Hicks, A.; Haughney, J.; Thomson, E.C.; van der Klaauw, A.A.; Kwok, J.; Libri, V.; Rampling, T.; Llewelyn, M.J.; Sharma, S.; McGregor, A.C.; Sturdy, A.; Moore, P.; Holliday, K.; Twelves, C.; Osanlou, O.; Osanlou, R.; Palfreeman, A.; Pan, D.; Regan, K.; Saralaya, D.; Sheridan, R.; Todd, S.; Charlton, S.; Hallis, B.; Ramsay, M.; Andrews, N.; Nguyen-Van-Tam, J.S.
Source
In: Journal of Infection . (Journal of Infection, June 2022, 84(6):795-813)
Subject
Language
English
ISSN
15322742
01634453
01634453